Near-complete adaptation of the PRiMA knockout to the lack of central acetylcholinesterase

J Neurochem. 2012 Sep;122(5):1065-80. doi: 10.1111/j.1471-4159.2012.07856.x. Epub 2012 Aug 3.

Abstract

Acetylcholinesterase (AChE) rapidly hydrolyzes acetylcholine. At the neuromuscular junction, AChE is mainly anchored in the extracellular matrix by the collagen Q, whereas in the brain, AChE is tethered by the proline-rich membrane anchor (PRiMA). The AChE-deficient mice, in which AChE has been deleted from all tissues, have severe handicaps. Surprisingly, PRiMA KO mice in which AChE is mostly eliminated from the brain show very few deficits. We now report that most of the changes observed in the brain of AChE-deficient mice, and in particular the high levels of ambient extracellular acetylcholine and the massive decrease of muscarinic receptors, are also observed in the brain of PRiMA KO. However, the two groups of mutants differ in their responses to AChE inhibitors. Since PRiMA-KO mice and AChE-deficient mice have similar low AChE concentrations in the brain but differ in the AChE content of the peripheral nervous system, these results suggest that peripheral nervous system AChE is a major target of AChE inhibitors, and that its absence in AChE- deficient mice is the main cause of the slow development and vulnerability of these mice. At the level of the brain, the adaptation to the absence of AChE is nearly complete.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / metabolism
  • Acetylcholinesterase / deficiency*
  • Acetylcholinesterase / metabolism
  • Adaptation, Physiological / drug effects
  • Adaptation, Physiological / genetics*
  • Animals
  • Animals, Newborn
  • Body Temperature / drug effects
  • Body Temperature / genetics
  • Brain / anatomy & histology
  • Brain / enzymology*
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacokinetics
  • Bungarotoxins / pharmacokinetics
  • Choline / metabolism
  • Cholinergic Agents / pharmacology
  • Cholinesterase Inhibitors / pharmacology
  • Collagen / deficiency
  • Dihydro-beta-Erythroidine / pharmacology
  • Dose-Response Relationship, Drug
  • Exploratory Behavior / drug effects
  • Exploratory Behavior / physiology
  • Gait / drug effects
  • Gait / genetics
  • Gene Expression Regulation / drug effects
  • Gene Expression Regulation / genetics*
  • In Vitro Techniques
  • Maze Learning / drug effects
  • Maze Learning / physiology
  • Membrane Potentials / drug effects
  • Membrane Potentials / genetics
  • Membrane Proteins / deficiency*
  • Mice
  • Mice, Knockout
  • Microdialysis
  • Motor Activity / drug effects
  • Motor Activity / genetics
  • Muscarinic Antagonists / pharmacokinetics
  • Muscle Proteins / deficiency
  • Nails, Ingrown
  • Neostigmine / pharmacology
  • Nerve Tissue Proteins / deficiency*
  • Neurons / drug effects
  • Neurons / physiology
  • Pirenzepine / analogs & derivatives
  • Pirenzepine / pharmacokinetics
  • Protein Binding / drug effects
  • Pyridines / pharmacokinetics
  • Radioisotopes / pharmacokinetics
  • Receptors, Muscarinic / metabolism
  • Rotarod Performance Test
  • Scopolamine / pharmacology
  • Spinal Cord / cytology
  • Statistics, Nonparametric
  • Tritium / pharmacokinetics

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Bungarotoxins
  • Cholinergic Agents
  • Cholinesterase Inhibitors
  • Membrane Proteins
  • Muscarinic Antagonists
  • Muscle Proteins
  • Nerve Tissue Proteins
  • Pyridines
  • Radioisotopes
  • Receptors, Muscarinic
  • prima1 protein, mouse
  • Tritium
  • AFDX 384
  • Dihydro-beta-Erythroidine
  • Neostigmine
  • Pirenzepine
  • Collagen
  • Scopolamine
  • Acetylcholinesterase
  • Colq protein, mouse
  • epibatidine
  • Choline
  • Acetylcholine